Loading...
Loading...
- Jazz Pharmaceuticals plc JAZZ has updated its full-year 2021 financial guidance to incorporate the GW Pharmaceuticals business, which the company acquired on May 5.
- Forecasts total net product sales of 3 billion to $3.1 billion in line with the consensus of $3.1 billion, compared to the earlier outlook of $2.5 billion - $2.7 billion.
- The majority of the sales comes from the neuroscience franchise, with a 2021 estimate of $2.3 billion - $2.4 billion versus $1.8 billion - $1.9 billion.
- Adjusted gross margin remains unchanged at 93%.
- The company expects adjusted EPS of $13.40 - $14.70 below the consensus of $15.05. Earlier guidance for adjusted EPS stood at $15.65 - $16.85.
- Jazz expects to generate 65% of 2022 revenues from products that have been launched or acquired since 2019.
- It also expects strong cash flows and hence targes less than 3.5x net leverage by the end of 2022.
- Price Action: JAZZ shares closed at $181.13 on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in